Skip to content
EDIVRO

News built for discoveryGEO · AEO · Agentic search

What is Edivro?Sign inSubmit news / Build profile
News

Explore Edivro

The business of what’s next.

News, company developments and ideas from across the Edivro publishing network.

Explore all stories

The front page

  • Latest storiesThe complete publication bank
  • Company news
  • Latest insights
  • Leadership news

Discover more

  • AI & innovation
  • People & profiles
  • Company features
  • Explore all topics
Stories. Connected.

Explore the Edivro story bank.

Explore all stories →
Explore the story bank →
What is Edivro?Editorial standards
Companies

Explore Edivro

Inside the businesses.

Company stories, brand profiles and announcements, with original dates and source attribution.

Explore company news

Companies & brands

  • Company news
  • Company features
  • Brand stories
  • Brand strategy

Explore business

  • Industry coverage
  • Leadership profiles
  • Business insights
  • Browse by location
Stories. Connected.

Explore the Edivro story bank.

Explore company news →
Explore the story bank →
What is Edivro?Editorial standards
Leaders & Profiles

Explore Edivro

The people behind the story.

Meet founders, executives and professionals through their work and published profiles.

Explore leader profiles

People to know

  • Featured leaders
  • Leadership stories
  • Young entrepreneurs
  • Newsmakers

Ideas & work

  • Leadership news
  • Workplace & culture
  • Company stories
  • Browse public profilesPeople behind the coverage
Stories. Connected.

Explore the Edivro story bank.

Explore leader profiles →
Explore the story bank →
What is Edivro?Editorial standards
Industries

Explore Edivro

A wider view of business.

Follow developments across sectors, from artificial intelligence to healthcare and real estate.

Explore all industries

Industry coverage

  • Artificial intelligence
  • Business
  • Real estate
  • Healthcare

More sectors

  • Manufacturing
  • Education
  • Fintech
  • All sectors & topics
Stories. Connected.

Explore the Edivro story bank.

Explore all industries →
Explore the story bank →
What is Edivro?Editorial standards
AI & Tech

Explore Edivro

Ideas changing the way we work.

Artificial intelligence, enterprise technology and the businesses building what comes next.

Explore AI coverage

AI & technology

  • Artificial intelligence
  • Technology stories
  • Enterprise AI & SaaS
  • Fintech & payments

News & insight

  • AI news
  • Industry insights
  • Company announcements
  • Research & ideas
Stories. Connected.

Explore the Edivro story bank.

Explore AI coverage →
Explore the story bank →
What is Edivro?Editorial standards
Press Room

Explore Edivro

Announcements. In context.

Find business announcements, company news and clearly labelled press releases.

Explore the Press Room

Read announcements

  • Company news & releasesAnnouncements from named issuers
  • Company news
  • Latest published stories
  • Browse industries

News by subject

  • Funding & investment
  • Appointments
  • Products & launches
  • Partnerships
Stories. Connected.

Explore the Edivro story bank.

Explore the Press Room →
Explore the story bank →
What is Edivro?Editorial standards
Work with Edivro

Create on Edivro

Choose how you work with Edivro.

Publishing for individuals and companies, client orders for agencies, and wider communications programmes for businesses.

Explore the three routes

Who you are

  • Individuals and companiesProfiles, stories and press releases
  • AgenciesPublishing for authorised clients
  • Corporate and businessPR, content, discovery and campaigns
  • Services & pricingCurrent per-article prices

Publishing tools

  • Build your profile
  • Submit your news
  • Edivro AI
  • How publishing works
Your next story.

Work with Edivro

Choose the route that fits your work.

Explore services
Explore the story bank →
What is Edivro?Editorial standards
Latest storiesCompany newsLeader profilesArtificial intelligence

Explore Edivro

News, companies and the people behind them.

News

Explore Edivro

The business of what’s next.

News, company developments and ideas from across the Edivro publishing network.

Explore all stories

The front page

  • Latest storiesThe complete publication bank
  • Company news
  • Latest insights
  • Leadership news

Discover more

  • AI & innovation
  • People & profiles
  • Company features
  • Explore all topics
Stories. Connected.

Explore the Edivro story bank.

Explore all stories →
Explore the story bank →
What is Edivro?Editorial standards
Companies

Explore Edivro

Inside the businesses.

Company stories, brand profiles and announcements, with original dates and source attribution.

Explore company news

Companies & brands

  • Company news
  • Company features
  • Brand stories
  • Brand strategy

Explore business

  • Industry coverage
  • Leadership profiles
  • Business insights
  • Browse by location
Stories. Connected.

Explore the Edivro story bank.

Explore company news →
Explore the story bank →
What is Edivro?Editorial standards
Leaders & Profiles

Explore Edivro

The people behind the story.

Meet founders, executives and professionals through their work and published profiles.

Explore leader profiles

People to know

  • Featured leaders
  • Leadership stories
  • Young entrepreneurs
  • Newsmakers

Ideas & work

  • Leadership news
  • Workplace & culture
  • Company stories
  • Browse public profilesPeople behind the coverage
Stories. Connected.

Explore the Edivro story bank.

Explore leader profiles →
Explore the story bank →
What is Edivro?Editorial standards
Industries

Explore Edivro

A wider view of business.

Follow developments across sectors, from artificial intelligence to healthcare and real estate.

Explore all industries

Industry coverage

  • Artificial intelligence
  • Business
  • Real estate
  • Healthcare

More sectors

  • Manufacturing
  • Education
  • Fintech
  • All sectors & topics
Stories. Connected.

Explore the Edivro story bank.

Explore all industries →
Explore the story bank →
What is Edivro?Editorial standards
AI & Tech

Explore Edivro

Ideas changing the way we work.

Artificial intelligence, enterprise technology and the businesses building what comes next.

Explore AI coverage

AI & technology

  • Artificial intelligence
  • Technology stories
  • Enterprise AI & SaaS
  • Fintech & payments

News & insight

  • AI news
  • Industry insights
  • Company announcements
  • Research & ideas
Stories. Connected.

Explore the Edivro story bank.

Explore AI coverage →
Explore the story bank →
What is Edivro?Editorial standards
Press Room

Explore Edivro

Announcements. In context.

Find business announcements, company news and clearly labelled press releases.

Explore the Press Room

Read announcements

  • Company news & releasesAnnouncements from named issuers
  • Company news
  • Latest published stories
  • Browse industries

News by subject

  • Funding & investment
  • Appointments
  • Products & launches
  • Partnerships
Stories. Connected.

Explore the Edivro story bank.

Explore the Press Room →
Explore the story bank →
What is Edivro?Editorial standards
Work with Edivro

Create on Edivro

Choose how you work with Edivro.

Publishing for individuals and companies, client orders for agencies, and wider communications programmes for businesses.

Explore the three routes

Who you are

  • Individuals and companiesProfiles, stories and press releases
  • AgenciesPublishing for authorised clients
  • Corporate and businessPR, content, discovery and campaigns
  • Services & pricingCurrent per-article prices

Publishing tools

  • Build your profile
  • Submit your news
  • Edivro AI
  • How publishing works
Your next story.

Work with Edivro

Choose the route that fits your work.

Explore services
Explore the story bank →
What is Edivro?Editorial standards

Your publishing workspace

Build a profile. Prepare your story. Manage orders and billing.

Sign in / create account
What is Edivro?How it worksServices & pricing

Search Edivro

Browse full results →
  1. EDIVRO/
  2. Stories
EDIVRO EditorialPharmaceuticals

Lupin reports US approval for phytonadione prefilled syringe

The announcement concerns a 1 mg/0.5 mL single-dose product and an abbreviated new drug application.

By Edivro Company News
India · 27 Oct 2026 · 1 min read
Share story ↓
Add as a Preferred Source on GoogleFind Edivro on Google News
Lupin reports US approval for phytonadione prefilled syringe — Edivro editorial illustration
EDIVROEditorial illustration

Edivro Company News · Original attributed summary. Source announcement: 2026-10-08.

At a glance

  • Lupin said the US Food and Drug Administration had approved its abbreviated new drug application for phytonadione injectable emulsion in a 1 mg/0.5 mL single-dose prefilled syringe.
  • Lupin cited estimated US annual sales of US$52.3 million for phytonadione injectable emulsion, using IQVIA moving annual total data through August 2026.

Lupin said the US Food and Drug Administration had approved its abbreviated new drug application for phytonadione injectable emulsion in a 1 mg/0.5 mL single-dose prefilled syringe. The company's announcement carries an October 8, 2026 dateline, although the webpage's publication metadata is dated October 9.

The company described the formulation as bioequivalent to the reference product from International Medication Systems. Its release identifies treatment and prevention of hypoprothrombinemia and vitamin K deficiency among the approved uses.

Is this a new molecule announcement?

The release concerns an abbreviated new drug application for a specified formulation. It is not an announcement of a newly discovered medicine or a comparison showing superior clinical outcomes.

What does the quoted market figure mean?

Lupin cited estimated US annual sales of US$52.3 million for phytonadione injectable emulsion, using IQVIA moving annual total data through August 2026. That estimate describes the cited product market, not Lupin's revenue or a sales forecast for its formulation.

The approval account here is attributed to Lupin's release. The article does not give dosing or treatment advice, and a product announcement should not replace the approved prescribing information or a clinician's assessment.

Questions about this story

These answers summarise the article and refer to its original reporting period.

Is this a new molecule announcement?

The release concerns an abbreviated new drug application for a specified formulation. It is not an announcement of a newly discovered medicine or a comparison showing superior clinical outcomes.

What does the quoted market figure mean?

Lupin cited estimated US annual sales of US$52.3 million for phytonadione injectable emulsion, using IQVIA moving annual total data through August 2026. That estimate describes the cited product market, not Lupin's revenue or a sales forecast for its formulation.

Sources and links

  • lupin.com — https://www.lupin.com/media/press-releases/lupin-receives-u-s-fda-approval-for-phytonadione-injectable-emulsion-usp
Request a correctionEditorial standards
PharmaceuticalsCompany NewsEdivro Daily 2026 10 27India

Publisher

Edivro Company News

Share this story

LinkedInFacebookXWhatsAppTelegramRedditPinterestThreadsBlueskyEmail

Pharmaceuticals

Related stories

Aman Mehta: Taking Torrent Pharma Into Its Next Era — Edivro editorial illustrationEDIVROEditorial illustration
EDIVRO News Profile

founder story

Aman Mehta: Taking Torrent Pharma Into Its Next Era

From strengthening India’s chronic-therapy leadership to integrating major acquisitions and shaping a broader growth agenda, Aman Mehta is emerging as one of the key next-generation leaders in Indian pharmaceuticals.

14 Sept 2026

EDIVRO News Profile feature from the imported archive. Original publication dates retained.

Lupin appoints Brian Savage to lead global legal and compliance functions — Edivro editorial illustrationEDIVROEditorial illustration
EDIVRO Editorial

news

Lupin appoints Brian Savage to lead global legal and compliance functions

The new president and chief legal officer will be based in New Jersey, according to Lupin’s appointment notice.

27 Oct 2026

Edivro Company News · Original attributed summary. Source announcement: 2026-10-23.

Pharma’s product pipeline includes both approved generics and early research bets — Edivro editorial illustrationEDIVROEditorial illustration
EDIVRO Editorial

analysis

Pharma’s product pipeline includes both approved generics and early research bets

Lupin’s formulation approval and Mankind’s proposed cell-therapy investment sit at different points in development.

27 Oct 2026

Edivro Industry · Analysis based on the primary sources linked in this article.

Original publication dates and source disclosures are retained. New submissions are reviewed before publication.

EDIVRO

Edivro publishes business news, company and leadership profiles, and industry analysis. Our publishing approach combines SEO, GEO and AEO with clear headlines, named sources and useful answers for readers and AI research agents.

Explore publishing on Edivro
Add as a Preferred Source on GoogleFind Edivro on Google News

About Edivro

  • About us
  • How it works
  • Editorial standards
  • Corrections & contact

Publish with Edivro

  • For creators
  • For agencies
  • For businesses
  • Pricing

Learn about discovery

  • Publishing for search and AI
  • SEO vs GEO vs AEO
  • Agentic search
  • Company announcements
  • Search discovery
  • Measure AI visibility

Explore Edivro

  • Latest stories
  • Industries
  • Company profiles
  • Leadership profiles
  • Press Room

© 2026 EDIVRO. All rights reserved.

Sign in / My StudioTerms & refundsPrivacySubscribe via RSS

Press releases are submitted content and are labelled as such.